Drug results: 1
| teprotumumab | Teprotumumab-trbw’s mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling |








Citing DrugCentral © 2025.
License